Abbott Laboratories 2014 Annual Report Download - page 28

Download and view the complete annual report

Please find page 28 of the 2014 Abbott Laboratories annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 80

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80

26
ABBOTT 2014 ANNUAL REPORT
TRANSFORMING
THE CONTINUUM
OF CARE
Abbott oers a broad range
of innovative diagnostics
instrument systems and solutions
for hospitals, reference labs,
molecular labs, blood banks,
physician oces, and clinics.
Our diagnostic products are
helping our customers better
meet the changing needs of
global healthcare. More than
simply tests or data points,
our diagnostic solutions work
together to help improve decision
making and patient care across
the spectrum of healthcare.
DIAGNOSTICS
2014 Business Review
2014 BUSINESS HIGHLIGHTS
• Announced European regulatory approval for the
Iridica system, a first-of-its-kind technology designed
to identify disease-causing pathogens, such as
bacteria, fungi or viruses, significantly faster than the
current standard of care
• Announced partnership with the U.S. Department
of Defense to develop portable blood tests for the
i-STAT point-of-care testing system to evaluate
potential concussions
• Launched ARCHITECT Clinical Chemistry
Hemoglobin A1c test, enabling physicians to quickly
assess a person’s average blood-glucose concentration
over several months, aiding in the diagnosis of
diabetes and helping identify patients who may be at
risk for developing the disease
• Demonstrated value of i-STAT point-of-care testing
system during the West African Ebola outbreak,
providing measures of key bodily functions while
keeping samples within quarantined areas
• Continued development of next-generation
hematology, blood-screening, immunochemistry,
molecular, and point-of-care testing platforms